SL Science Lists on Nasdaq, Secures $7.8M PIPE Financing
SL Science Holding Limited announced its full-year 2025 financial results, reporting a 35% decrease in net revenue to $2.20 million and a net loss of $3.82 million, primarily due to a strategic shift from direct retail sales to corporate distribution channels to focus on R&D. Despite the financial decline, the company highlighted its recent successful business combination and listing on the Nasdaq Global Market, along with a concurrent $7.8 million PIPE financing. This capital infusion is expected to provide financial flexibility to accelerate growth, attract talent, facilitate acquisitions, and support clinical operating requirements, with a focus on advancing its Gamma Delta T (GDT) cell therapy pipeline.
Key Highlights
- SL Science completed its business combination and listed on Nasdaq Global Market under "SLBT" on June 12, 2026.
- Concurrently closed a $7.8 million PIPE financing to accelerate growth and fund R&D initiatives.
- Full-year 2025 net revenue decreased 35% to $2.20 million, down from $3.36 million in 2024.
- Gross profit decreased 60% to $0.78 million for 2025, impacted by a wholesale transition.
- Net loss for 2025 was $3.82 million, a 221% increase from $1.19 million in 2024.
- Research and development expenses remained robust at $2.07 million in 2025.
- Cash, cash equivalents, and restricted cash stood at $1.26 million as of December 31, 2025.
- A Pre-IND meeting and formal IND submission for CD-19 Armed-T blood cancer program targeted for Q1 2027.
Price Impact
More from SLBT